VITA 34 AG Cash Flow Conversion Efficiency

Latest as of December 2025: 0.078x

VITA 34 AG cash flow conversion efficiency. Based on the latest financial reports, VITA 34 AG (V3V) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€425.00K ≈ $496.87K USD) by net assets (€5.42 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of VITA 34 AG (2006–2025)

Cash flow conversion efficiency of VITA 34 AG from 2006 to 2025. This chart illustrates how VITA 34 AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View V3V share price today for real-time trading data and today's change.

VITA 34 AG Cash Flow Conversion Ratio Explained

VITA 34 AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

VITA 34 AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of VITA 34 AG ranked by their cash flow conversion efficiency. Also see how much is VITA 34 AG worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Bluecom Co. Ltd
KQ:033560
0.002x
Maan Aluminium Limited
NSE:MAANALU
0.076x
Samchem Holdings Bhd
KLSE:5147
0.099x
Halla Eng&Cons
KO:014790
-0.073x
Choheung
KO:002600
-0.209x
West Vault Mining
V:WVM
-0.004x
Gold Rain Enterprises
TWO:4503
-0.001x
Cryomax Cooling System Corp
TW:1587
0.052x

Annual Cash Flow Conversion Efficiency for VITA 34 AG (2006–2025)

The table below shows the annual cash flow conversion efficiency of VITA 34 AG from 2006 to 2025. Review VITA 34 AG free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €5.42 Million
≈ $6.33 Million
€3.88 Million
≈ $4.53 Million
0.716x +6.75%
2024-12-31 €12.91 Million
≈ $15.09 Million
€8.65 Million
≈ $10.12 Million
0.671x +66.85%
2023-12-31 €22.77 Million
≈ $26.63 Million
€9.15 Million
≈ $10.70 Million
0.402x +242.02%
2022-12-31 €15.85 Million
≈ $18.53 Million
€-4.49 Million
≈ $-5.24 Million
-0.283x -535.27%
2021-12-31 €41.94 Million
≈ $49.03 Million
€2.73 Million
≈ $3.19 Million
0.065x -51.75%
2020-12-31 €29.54 Million
≈ $34.53 Million
€3.98 Million
≈ $4.65 Million
0.135x -35.44%
2019-12-31 €30.27 Million
≈ $35.39 Million
€6.32 Million
≈ $7.39 Million
0.209x +34.13%
2018-12-31 €29.55 Million
≈ $34.54 Million
€4.60 Million
≈ $5.38 Million
0.156x +201.50%
2017-12-31 €29.64 Million
≈ $34.66 Million
€1.53 Million
≈ $1.79 Million
0.052x -46.63%
2016-12-31 €23.65 Million
≈ $27.65 Million
€2.29 Million
≈ $2.67 Million
0.097x -11.30%
2015-12-31 €23.76 Million
≈ $27.77 Million
€2.59 Million
≈ $3.03 Million
0.109x +129.00%
2014-12-31 €22.16 Million
≈ $25.91 Million
€1.05 Million
≈ $1.23 Million
0.048x -42.89%
2013-12-31 €21.29 Million
≈ $24.89 Million
€1.77 Million
≈ $2.08 Million
0.083x -16.21%
2012-12-31 €20.49 Million
≈ $23.96 Million
€2.04 Million
≈ $2.38 Million
0.099x +391.47%
2011-12-31 €20.01 Million
≈ $23.39 Million
€-683.00K
≈ $-798.50K
-0.034x -163.72%
2010-12-31 €18.82 Million
≈ $22.00 Million
€1.01 Million
≈ $1.18 Million
0.054x -12.02%
2009-12-31 €18.87 Million
≈ $22.06 Million
€1.15 Million
≈ $1.34 Million
0.061x +137.50%
2008-12-31 €18.11 Million
≈ $21.17 Million
€-2.94 Million
≈ $-3.44 Million
-0.162x -92.47%
2007-12-31 €19.73 Million
≈ $23.07 Million
€-1.66 Million
≈ $-1.95 Million
-0.084x -219.93%
2006-12-31 €12.94 Million
≈ $15.12 Million
€-341.00K
≈ $-398.66K
-0.026x --

About VITA 34 AG

XETRA:V3V Germany Medical Care Facilities
Market Cap
$56.66 Million
€48.46 Million EUR
Market Cap Rank
#21225 Global
#1907 in Germany
Share Price
€2.78
Change (1 day)
-0.36%
52-Week Range
€2.68 - €6.85
All Time High
€17.30
About

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more